Ceftolozane/tazobactam: a new option in the treatment of complicated gram-negative infections.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264669 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Background: Ceftolozane-tazobactam and ceftazidime-avibactam are preferred treatment options for multidrug-resistant Pseudomonas aeruginosa infections; however, real-world comparative effectiveness studies are scarce. Pharmacokinetic and pharmacodynamic differences between the agents might affect clinical response rates. We aimed to compare the effectiveness of ceftolozane-tazobactam and ceftazidime-avibactam for treatment of invasive multidrug-resistant P aeruginosa infections.
View Article and Find Full Text PDFActivity of ceftolozane/tazobactam and comparators against gram-negative bacilli: Results from the Study for Monitoring Antimicrobial Resistance Trends (SMART - Brazil), 2018‒2021.
Braz J Infect Dis
December 2024
Global Medical & Scientific Affairs (GMSA), MSD Brazil, São Paulo, SP, Brazil.
Increased spread of antimicrobial resistance by Gram-Negative Bacilli (GNB) poses a global challenge, with exacerbated burden post-pandemic. The aim of this study was to investigate the in vitro activity of ceftolozane/tazobactam and its comparators against the frequently identified GNB isolated from patients admitted to Brazilian medical sites between the year 2018‒2019 and 2020‒2021. The impact of pandemic on antimicrobial resistance and presence of β-lactamase genes were also evaluated.
View Article and Find Full Text PDFInsights into the Rising Threat of Carbapenem-Resistant Enterobacterales and Epidemic Infections in Eastern Europe: A Systematic Literature Review.
Antibiotics (Basel)
October 2024
Merck & Co., Inc., Rahway, NJ 07065, USA.
Background: Antimicrobial resistance is a major global public health challenge, particularly with the rise of carbapenem-resistant Enterobacterales (CRE) and (CRPA). This study aimed to describe the characteristics of CRE and CRPA infections in Eastern Europe, focusing on Bulgaria, Croatia, Czechia, Greece, Hungary, Poland, Romania, Serbia, Slovakia, and Slovenia.
Methods: Following MOOSE and PRISMA guidelines, a systematic literature review of articles published between 1 November 2017 and 1 November 2023 was conducted using the MEDLINE, Embase, Web of Science, CDSR, DARE, and CENTRAL databases.
Recent updates in treating carbapenem-resistant infections in patients with hematological malignancies.
Expert Rev Anti Infect Ther
December 2024
Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Hacettepe University, Ankara, Türkiye.
Article Synopsis
- * The optimal treatment for certain resistant infections is ceftazidime/avibactam, with other alternatives like imipenem/cilastatin/relebactam and meropenem/vaborbactam serving as backup options, especially for KPC-positive cases.
- * Emerging treatment strategies involve using combinations such as ceftazidime/avibactam with aztreonam for tougher infections, while AI-driven risk models can help predict infection risks in vulnerable patients.
Effectiveness and safety of Ceftolozane/Tazobactam administered in continuous infusion through elastomeric pumps in OPAT regimen: a case series.
Infect Dis (Lond)
October 2024
UOC Malattie Infettive, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.
Purpose: This study aimed to present real-life data on the use, effectiveness, and safety of administering Ceftolozane/Tazobactam (C/T) through elastomeric pumps (EP) in the outpatient setting.
Methods: This case series study was conducted from January 2022 to July 2023 in a large University Hospital in Rome, Italy. Patients receiving continuous infusion of C/T EP were included up to a follow-up period of 90 days after the end of antibiotic therapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!